$650 Million Pradaxa Settlement
After over two years of hard work, Ashcraft & Gerel is pleased to announce that the Pradaxa litigation has resolved through settlement with the drug manufacturer Boehringer Ingelheim. The settlement encompasses almost 4,000 claimants across the country for an aggregate total of $650 million. The settlement compensates those who allege they were injured or died as a result of uncontrolled bleeding caused by Pradaxa.
The FDA approved Pradaxa as a blood thinning medication in fall 2010. Its popularity as a new, better alternative to other blood thinner was quickly apparent: As of 2011, over $1 billion in Pradaxa prescriptions were sold. However, Pradaxa’s side effects proved to be dangerous for many of the patients who took the medication. Side effects include:
- Cerebral hemorrhaging
- Internal Bleeding
Michelle Parfitt, partner and a leader of our pharmaceutical and medical device litigation team at Ashcraft & Gerel, was appointed to the Plaintiffs’ Executive Committee in September 2012 by Chief Judge Richard Herndon in the U.S. District Court for the Southern District of Illinois. Ashcraft & Gerel also played a pivotal role on the science and expert committee. Additionally, Ashcraft & Gerel teamed up with the Meneo Law Group to establish the Connecticut docket for Pradaxa cases.
Ashcraft & Gerel would like to thank all those involved in securing justice for those injured by using Pradaxa.